| Type | Public |
|---|---|
| Traded as | LSE: BGC |
| Industry | Pharmaceuticals |
| Founded | 1991 as British Technology Group Ltd. |
| Headquarters | London, United Kingdom |
| Key people | John Brown (Chairman of the board), Louise Makin (CEO) |
| Products | Development and licensing of critical care, cancer, neurological and other treatments |
| Revenue | £98.5 million (2010)[1] |
| Operating income | £10.8 million (2010)[1] |
| Profit | £11.3 million (2010)[1] |
| Employees | 292 (2010)[1] |
| Website | www.btgplc.com |
BTG plc (LSE: BGC), a public limited company is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products. The company is a constituent of the FTSE 250 Index.
Contents |
In 1948, the National Research Development Corporation was formed with the purpose of commercialising innovations that arose from public funded research.[2] This was complemented in November 1975 by the establishment of the National Enterprise Board to implement the then-Government's policy of moving public sector industry into commercial private enterprise.[3]
These two organisations were merged by the Government in 1981 to form a new, non-statutory body called the British Technology Group.[4] It acted principally as a technology transfer company, licencing and commercialising the use of publicly-funded developments. The Group was put onto a statutory footing in the British Technology Group Act, 1991[5] with HM Treasury initially being the only shareholder. Subsequently, in March 1992, Cinven arranged a management buy-out from the Government. The company later floated on the London Stock Exchange in 1995.[2] Three years later, on 27 May 1998, the Group adopted its present name. It now focuses its work on developing and commercialising medical innovations.[2]
Since acquiring the commercialisation rights to magnetic resonance imaging (MRI) (under a revenue share scheme) in 1983, BTG has come to licence a large part of the world market in MRI, including licencees such as General Electric and Philips.[6]
BTG earns revenues from product sales and royalties from marketed products. These include CroFab, an antidote used to treat mild or moderate envenomation from Crotalid snakes, which includes rattlesnakes, found in the US and DigiFab, an antidote to treat patients with life-threatening digoxin (digitalis) toxicity or overdose.
The Company's active development pipeline includes the following products:[7]
In addition BTG has several programmes it intends to partner as they reach key development milestones.
|
||||||||